Repligen closes $1.5 billion BioLife Solutions deal, pushing deeper into cell therapy
Repligen has wrapped up its $1.5 billion buyout of BioLife Solutions, bringing in a lineup of cell processing tools and biopreservation media to boost its standing in the cell and gene therapy field.